Stuttgart - Delayed Quote • EUR
Sangamo Therapeutics Inc (GBY.SG)
At close: April 24 at 1:57 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
176,232.0000
176,232.0000
111,299.0000
110,701.0000
118,192.0000
Operating Expense
295,224.0000
295,224.0000
312,580.0000
294,038.0000
247,744.0000
Operating Income
-118,992.0000
-118,992.0000
-201,281.0000
-183,337.0000
-129,552.0000
Net Non Operating Interest Income Expense
11,102.0000
11,102.0000
9,432.0000
5,346.0000
8,775.0000
Other Income Expense
-155,013.0000
-155,013.0000
--
--
--
Pretax Income
-262,903.0000
-262,903.0000
-191,849.0000
-177,991.0000
-120,777.0000
Tax Provision
-5,072.0000
-5,072.0000
429.0000
306.0000
345.0000
Net Income Common Stockholders
-257,831.0000
-257,831.0000
-192,278.0000
-178,286.0000
-120,996.0000
Diluted NI Available to Com Stockholders
-257,831.0000
-257,831.0000
-192,278.0000
-178,286.0000
-120,996.0000
Basic EPS
-1.48
-1.48
-1.25
-1.23
-0.90
Diluted EPS
-1.48
-1.48
-1.25
-1.23
-0.90
Basic Average Shares
174,444.0000
174,444.0000
154,345.0000
144,568.0000
134,449.0000
Diluted Average Shares
174,444.0000
174,444.0000
154,345.0000
144,568.0000
134,449.0000
Total Operating Income as Reported
-274,005.0000
-274,005.0000
-201,281.0000
-183,337.0000
-129,552.0000
Total Expenses
295,224.0000
295,224.0000
312,580.0000
294,038.0000
247,744.0000
Net Income from Continuing & Discontinued Operation
-257,831.0000
-257,831.0000
-192,278.0000
-178,286.0000
-120,996.0000
Normalized Income
-105,808.5552
-105,808.5552
-192,278.0000
-178,286.0000
-120,996.0000
Interest Income
11,102.0000
11,102.0000
9,432.0000
5,346.0000
8,775.0000
Net Interest Income
11,102.0000
11,102.0000
9,432.0000
5,346.0000
8,775.0000
EBIT
-118,992.0000
-118,992.0000
-201,281.0000
-183,337.0000
-129,552.0000
EBITDA
-96,800.0000
-96,800.0000
-180,719.0000
-165,699.0000
-116,183.0000
Reconciled Depreciation
22,192.0000
22,192.0000
20,562.0000
17,638.0000
13,369.0000
Net Income from Continuing Operation Net Minority Interest
-257,831.0000
-257,831.0000
-192,278.0000
-178,286.0000
-120,996.0000
Total Unusual Items Excluding Goodwill
-155,013.0000
-155,013.0000
--
--
--
Total Unusual Items
-155,013.0000
-155,013.0000
--
--
--
Normalized EBITDA
58,213.0000
58,213.0000
-180,719.0000
-165,699.0000
-116,183.0000
Tax Rate for Calcs
0.0000
0.0000
0.0002
0.0003
0.0003
Tax Effect of Unusual Items
-2,990.5552
-2,990.5552
--
--
--
12/31/2020 - 12/28/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade